New engineered amplification reagents are being developed to address ongoing workflow challenges in molecular diagnostics, with a focus on speed, robustness, and performance in complex sample types.
Watchmaker Genomics has introduced Stellar RT-qPCR and qPCR Kits alongside its recombinase polymerase amplification (RPA) enzyme suite, expanding its molecular diagnostics tools beyond next-generation sequencing applications. The systems are designed to support both PCR-based and isothermal amplification workflows used in assay development.
The PCR kits use engineered enzymes, including StellarTaq DNA polymerase and StellarScript HT+ reverse transcriptase, designed to improve inhibitor tolerance and maintain performance in crude or minimally processed samples. According to the company, the chemistry enables rapid cycling workflows that can deliver results in under 10 minutes on fast-cycling platforms.
A key focus is improving amplification performance in challenging sample matrices, an area that often limits workflow efficiency in clinical molecular testing due to the need for extensive nucleic acid extraction and purification steps.
In parallel, the RPA enzyme suite provides an isothermal amplification option that operates at a constant temperature, removing the need for thermal cycling. The approach is intended for use in decentralized and point-of-care settings where simplified instrumentation and rapid turnaround are critical.
While PCR remains the dominant method in clinical molecular diagnostics, demand continues to grow for faster and more flexible workflows that can reduce time to result and expand testing outside centralized laboratories. Enzyme engineering approaches that enhance speed and inhibitor tolerance are increasingly central to these efforts.
Watchmaker Genomics will present performance data on its amplification systems at ESCMID 2026 in Munich, including results from its RT-qPCR and qPCR platforms.
Note: This news summary was generated by AI based on a published press release, followed by a review from human editors.
